Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
  • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
  • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
  • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
  • C07D251/40—Nitrogen atoms
  • C07D251/54—Three nitrogen atoms
  • C07D251/70—Other substituted melamines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents

Definitions

• This invention relates to novel 2,4,6-triamino- 1,3,5-triazines, compositions containing them, processes for making them and their use in the treatment of
• carcinomas particularly ovarian carcinomas.
• Trimelamol (1) [2,4,6- tris ⁇ (hydroxymethyl)(methyl) amino)-1,3,5-triazine] is clinically active, particularly against ovarian carcinomas, but its clinical development has been halted due to
• R 3 is hydrogen, alkyl or hydroxymethyl
• R 1 and R 2 are hydrogen, alkyl or an electron-withdrawing organic group containing at least two carbon atoms, at least one of R 1 and R 2 being an electron withdrawing group, and
• R 3 when R 3 is hydroxymethyl, R 1 and R 2 are electron-withdrawing organic groups.
• Preferred electron-withdrawing organic groups are -CH 2 CF 3 and -CH 2 C ⁇ CH.
• the compounds of the present invention are prepared via novel intermediate compounds of the general formula:
• R 3a and R 3b are hydrogen, alkyl or hydroxymethyl, but not both hydroxymethyl
• R 1 and R 2 are hydrogen, alkyl or an electron-withdrawing organic group which is an electron-withdrawing organic group containing at least two carbon atoms, and at least one of R 1 and R 2 being an electron-withdrawing organic group.
• aqueous acetone or other suitable aqueous media may be regarded as a pro-drug form of that product in biological test systems.
• the compounds of this invention are clinically active and are of use against ovarian carcinomas
• compositions which comprise, as active ingredient, at least one compound of general formula I, in association with a pharmaceutically
• the compounds of the invention will normally be administered orally or by injection.
• compositions for parenteral administration will normally be solutions in aqueous saline, which is pyrogen free for human use. Such compositions can be administered intravenously or intraperitoneally.
• compositions for oral administration will mostly be in solid or liquid form, mostly as tablets, capsules, lozenges, etc.
• Liquid compositions can be
• solutions or dispersions in aqueous or non-aqueous media are of neutral or alkaline pH and of low ionic strength e.g. 5% dextrose.
• Suitable daily doses of the compounds of the invention in therapeutic treatment of the human or animal body range from about 100mg to 3g/m 2 body-surface.
• Table 2 shows that none of the compounds tested showed in vivo activity, against ADJ/PC6 tumour,comparable with (1).
• the poor activity relative to (1) appears intrinsic since Table 3, which shows the activity of (5), (6) and (13) against a variety of non-ovarian cell lines shows (1) to be greater than 3-fold more potent against the ADJ/PC6 tumour cell line in vitro than the other compounds.
• Table 4 shows that the trifluoroethyl analogues (5) and (6) are virtually equipotent with (1) in a variety of ovarian cell lines, as is the propargyl analogue (13). Of particular interest is that compounds (5) and (13) show high activity against cisplatin-resistant cell-lines.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Priority Applications (1)

Applications Claiming Priority (2)

Publications (1)

Family

ID=10692068

Family Applications (1)

Country Status (11)

Families Citing this family (7)

• 1991
  • 1991-03-22 GB GB919106170A patent/GB9106170D0/en active Pending
• 1992
  • 1992-03-20 IE IE088992A patent/IE920889A1/en unknown
  • 1992-03-20 ZA ZA922073A patent/ZA922073B/xx unknown
  • 1992-03-20 IL IL101317A patent/IL101317A0/xx unknown
  • 1992-03-20 MX MX9201258A patent/MX9201258A/es unknown
  • 1992-03-21 TW TW081102138A patent/TW202437B/zh active
  • 1992-03-23 JP JP4506407A patent/JPH06511229A/ja active Pending
  • 1992-03-23 WO PCT/GB1992/000525 patent/WO1992016513A1/en not_active Ceased
  • 1992-03-23 EP EP92302491A patent/EP0505220A1/en not_active Ceased
  • 1992-03-23 AU AU15667/92A patent/AU1566792A/en not_active Abandoned
  • 1992-03-23 CA CA002106868A patent/CA2106868A1/en not_active Abandoned

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events